Mucins as anti-cancer targets: perspectives of the glycobiologist
| Autor: | Jacob Melamed, Inka Brockhausen |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_treatment
Biology Cancer Vaccines Biochemistry Epitope 03 medical and health sciences Neoplasms medicine Humans Molecular Biology MUC1 030304 developmental biology chemistry.chemical_classification 0303 health sciences Membrane Glycoproteins 030302 biochemistry & molecular biology Mucin Mucins Cancer Cell Biology Immunotherapy medicine.disease carbohydrates (lipids) chemistry Cancer cell Cancer research biology.protein Antibody Glycoprotein |
| Zdroj: | Glycoconjugate Journal. 38:459-474 |
| ISSN: | 1573-4986 0282-0080 |
| Popis: | Mucins are highly O-glycosylated glycoproteins that carry a heterogenous variety of O-glycan structures. Tumor cells tend to overexpress specific mucins, such as the cell surface mucins MUC1 and MUC4 that are engaged in signaling and cell growth, and exhibit abnormal glycosylation. In particular, the Tn and T antigens and their sialylated forms are common in cancer mucins. We review herein methods chosen to use cancer-associated glycans and mucins as targets for the design of anti-cancer immunotherapies. Mucin peptides from the glycosylated and transmembrane domains have been combined with immune-stimulating adjuvants in a wide variety of approaches to produce anti-tumor antibodies and vaccines. These mucin conjugates have been tested on cancer cells in vitro and in mice with significant successes in stimulating anti-tumor responses. The clinical trials in humans, however, have shown limited success in extending survival. It seems critical that the individual-specific epitope expression of cancer mucins is considered in future therapies to result in lasting anti-tumor responses. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink